The 2025 World Bronchiectasis Conference highlighted new research on bronchiectasis and NTM - plus an emerging ...

Topline results were announced from a second phase 3 trial evaluating AD109 (aroxybutynin 2.5mg/atomoxetine 75mg) in patients with OSA.

HHS Secretary RFK Jr is considering removing all 16 members of an advisory group that helps decide which preventive services should be fully covered by insurance.

New research has revealed factors associated with an increased risk of COVID-19-related death and hospitalization among patients with cancer.

The US Environmental Protection Agency is looking to remove the legal underpinning for most regulations against climate change.

The controversial preservative thimerosal will be stripped from all flu vaccines distributed in the United States.

Among children studied, causes of bronchiectasis were most commonly post-infective (31%), primary and secondary immunodeficiencies (19%), and genetic (13%). Children and teens with bronchiectasis and ...

A QI project shows that the establishment of an interdisciplinary Code Sepsis Team can improve compliance with sepsis bundle ...

The Food and Drug Administration has granted Fast Track Designation to ateganosine for the treatment of non-small cell lung cancer.

Adults with pediatric-onset bronchiectasis have increased disease severity compared with those with adult-onset bronchiectasis.

Despite near universal availability of nirsevimab, only 35% of eligible children receive nirsevimab for RSV prophylaxis.

A broad spectrum of systemic inflammatory manifestations defines VEXAS syndrome, with cutaneous, respiratory, and vascular involvement commonly reported.